[Protection of the heart from reperfusion injury and ineffective oxygen using inhibitors of the mitochondrial permeability transitional pore].
In experiments on isolated hearts of guinea-pig, perfused under Langendorff preparation, possible protection of hearts from reperfusion injury by the known inhibitors of mitochondrial permeability transition pore--cyclosporin A, and trolox--water-soluble vitamin E was studied. It has been shown that cardiac reperfusion was followed with an increase in an oxygen cost of myocardial work (by 83% from control level in 40 min of reperfusion), in addition to the disturbances of cardiac contractility, tone of the coronary vessels and heart rate. The heart function and myocardial oxygen metabolism disturbances, due to global 20 min ischaemia and reperfusion, were essentially decreased by a preliminary application of investigated agents. Trolox improved cardiac recovery both when it was perfused in vitro and after its administration per os. In 40 min of heart reperfusion LVdeveloped pressure was 79% as compared to 51% in that at control; dP/dtmax and dP/dtmin were 88% and 85% accordingly against 66% and 45% in control; oxygen cost of myocardial work didn't change reliably).


CONCLUSIONS
Postreperfusion disturbances of cardiac contractility, tone of the coronary vessels and heart rate, as well as noneffective oxygen utilization by the heart tissue were due to an opening of mitochondrial permeability transition pore.
Sahach
V F
VF
A.A. Bogomoletz Institute of Physiology NAS Ukraine, Kiev.
Shimans'ka
T V
TV
Nadtochiĭ
S M
SM
D000818:Animals; D002316:Cardiotonic Agents / Q000494:pharmacology*; D002839:Chromans / Q000494:pharmacology; D016572:Cyclosporine / Q000494:pharmacology; D006168:Guinea Pigs; D066298:In Vitro Techniques; D007425:Intracellular Membranes / Q000378:metabolism*; D008929:Mitochondria, Heart / Q000378:metabolism*; D009200:Myocardial Contraction / Q000187:drug effects / Q000502:physiology; D015428:Myocardial Reperfusion Injury / Q000378:metabolism / Q000503:physiopathology / Q000517:prevention & control*; D010101:Oxygen Consumption / Q000187:drug effects* / Q000502:physiology; D010539:Permeability / Q000187:drug effects; D016277:Ventricular Function, Left / Q000187:drug effects* / Q000502:physiology
D002316:Cardiotonic Agents; D002839:Chromans; D016572:Cyclosporine; C010643:6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid